Denali Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Denali Therapeutics Inc in the third quarter 2026?
Denali Therapeutics Inc achieved a return on average equity (ROE) of 21.4 % in its third quarter 2026, this is above DNLI's average return on equity of -7.43%.
Denali Therapeutics Inc shareholder's equity over the 12 months ending in its third quarter 2026 are valued at $925 million

ROE has advanced compared to 0.11% in the second quarter 2026, due to net income growth.

Within the Biotechnology & Pharmaceuticals industry 11 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2026 from 2256 to 2293.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Equity Change	0.02 %	-18.68 %	-17.51 %	-17.56 %	-
Y / Y Net Income Change	-	-	-	24.66 %	-
Net Income (TTM) in Millions	198	1	4	0	-76
Return On Equity (TTM)	21.4 %	0.11 %	0.45 %	-0.01 %	-7.06 %
DNLI's Total Ranking	# 2293	# 2256	# 1705	# 2194	#
Equity (TTM) in Millions	926	835	926	1,014	926
Seq. Equity Change	10.92 %	-9.82 %	-8.65 %	9.45 %	-9.82 %
Seq. Net Income Change	-	-	-	-	-

Back to DNLI Management Effectiveness >> DNLI's 5 Years Annual ROE >> Compare DNLI ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 12
Sector	# 77
Overall	# 2293

Return On Equity Statistics
High	Average	Low
32.16 %	-7.43 %	-48.73 %
(Jun 30 2023)		(Dec 31 2021)

DNLI Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	1,014	1,230	1,031	1,042	962
Y / Y Equity Change	-17.56 %	19.28 %	-1.1 %	8.33 %	-16.36 %
Net Income in Millions	0	0	0	0	1
Y / Y Net Income Change	-	-	-	-	-99.6 %
Return On Equity	-0.01 %	-0.01 %	-0 %	-0 %	0.06 %

Back to DNLI Management Effectiveness >> DNLI's 5 Years Annual ROE >> Compare DNLI ROE to its Competitors

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
DNLI's' Return on Equity at Yahoo Finance
DNLI's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for DNLI's Competitors
Subscribers only: Roe for Denali Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for DNLI's Customers

Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector	ROE
Tenet Healthcare Corp	57.13 %
Aurinia Pharmaceuticals Inc	51.92 %
Nurix Therapeutics Inc	49.34 %
Carlisle Companies Incorporated	44.18 %
Bristol myers Squibb Company	43.83 %
Zevra Therapeutics Inc	38.02 %
Dexcom Inc	36.56 %
Rallybio Corporation	36.35 %
Caredx Inc	34.08 %
Chemed Corporation	32.10 %
Illumina Inc	31.45 %
Protalix Biotherapeutics inc	30.74 %
Transmedics Group Inc	28.74 %
Acadia Pharmaceuticals Inc	28.03 %
Pro dex Inc	26.91 %
Sotera Health Company	26.41 %
Pacs Group Inc	25.65 %
Standard Biotools Inc	25.58 %
Resmed Inc	25.50 %
Bioventus Inc	24.60 %
Encompass Health Corporation	24.08 %
Iradimed Corporation	23.90 %
Electromed Inc	23.73 %
Corcept Therapeutics Inc	22.88 %
Msa Safety Inc	21.79 %
Lantheus Holdings Inc	21.72 %
Iqvia Holdings Inc	21.40 %
Denali Therapeutics Inc	21.40 %
West Pharmaceutical Services Inc	21.08 %
Brightspring Health Services Inc	20.31 %

Date modified: 2026-11-04T16:54:19+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.